To assess pharmacological cardiotoxicity, it was common practice to measure QT interval in vivo and the blockage of potassium channel. Nevertheless, a new paradigm has been developed to overcome the limits of the previous one since 2013. In fact, it has been demonstrated that the old paradigm was stringent, labeling as pro-arrhythmic some pharmacological compounds which actually were not.